Back to Newsroom
Back to Newsroom

Dr. Randal Dull Joins BioFuse Medical Technologies, Inc. Scientific Advisory Board

Tuesday, 11 July 2023 09:45 AM

BioFuse Medical Technologies, Inc.

MELBOURNE, FL / ACCESSWIRE / July 11, 2023 / BioFuse Medical Technologies, Inc, a pioneering medical device company, is delighted to announce the appointment of Randal Dull, MD PhD to its Scientific Advisory Board. Dr. Dull, a distinguished physician-executive, clinician-scientist and healthcare consultant, brings his exceptional expertise and extensive accomplishment to contribute to the development of BioFuse's revolutionary surgical solutions.

Dr. Dull is currently a Tenured Full Professor at the University of Arizona College of Medicine in Tucson, AZ. He is an internationally recognized anesthesiologist with research expertise in cardiovascular and pulmonary physiology, vascular inflammation, the endothelial glycocalyx and fluid resuscitation. Dr. Dull's impressive career includes being an NIH-funded principal investigator and former recipient of two endowed chairs: the Baker Chair in Anesthesiology ($2.8M) at the University of Arizona and the Presidential Endowed Chair in Anesthesiology ($1.5M) at the University of Utah.

With over 20+ years of clinical anesthesia experience, Dr. Dull remains actively involved in patient care, focusing on anesthesia for hepatobiliary, pancreatic and surgical oncology cases. His scientific expertise aligns directly with providing exceptional patient care in these specialized areas. Dr. Dull has held leader positions in academic anesthesiology, serving as Research Director, Vice Chair and Department Chair at multiple tier-1 research universities. As Chairman, he significantly rebuilt a department through strategic recruitment, creating transparency and accountability, realigning compensation with clinical work and expanding anesthesia coverage across a growing clinical enterprise.

Dr. Dull's contribution to the field extends beyond academia. He has participated on NIH study sections, served as a Senior Editor for the International Anesthesia Research Society's journal Anesthesia & Analgesia, and participated on the American Society of Anesthesiology Committees on Critical Care and Committee on Clinical Circulation. He also served on the Scientific Advisory Board for the Association of University Anesthesiologist and the American Heart Association Vascular Wall Study Section, among others. Dr. Dull has been an ad hoc reviewer for prestigious journals including Nature Medicine, Anesthesiology, and Journal of Physiology.

As a thought leader in the field of vascular biology, Dr. Dull has made significant contributions to the understanding of the endothelial glycocalyx, mechano-transduction and vascular barrier regulation. Dr. Dull has been a consultant and Key Opinion Leader for pharmaceutical companies, advising on matters related to acute lung injury and inhaled drug delivery. His expertise in technology management has played a crucial role in evaluating and assessing the science and commercialization potential of new therapeutic compounds and devices.

"We are thrilled to have Dr. Randal Dull join our Scientific Advisory Board" said Dr. Joseph Stauffer, Chairman of BioFuse Medical Technologies. "His broad-ranging and exceptional expertise and deep understanding of healthcare and medical innovation will be invaluable as we continue to advance BioFuse and develop cutting-edge surgical solutions. Dr Dull's wealth of knowledge in cardiovascular and pulmonary physiology, vascular inflammation and tissue mechanics will greatly contribute to our mission of improving patient care".

## About BioFuse Medical Technologies, Inc.

BioFuse Medical Technologies' first product offering, SurgiFuse® is a new RF tissue sealing and welding technology. Using transformative technology, demonistrated in Europe in thousands of cases, this surgical innovation replaces traditional methods of sutures, staples, and electrosurgical vessel sealing. SurgiFuse® is a platform technology that can address a broad range of clinical applications, includes a robust pipeline of products in various stages of development, solid IP protection and trade secrets.

SurgiFuse® is an advanced high-frequency electrosurgical system that incorporates a unique and proprietary way of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the proprietary use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, energy output to the tissue occurs in pulses. These computer-controlled energy pulses create optimal temperatures that unravel large molecules in the tissue and as these molecules cool, they become intertwined and create a fusion.

This technology will serve a large and growing target market of $3 billion. Market data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improved patient outcomes. Surgeons are looking for new technology that will eliminate scars and lower leakage and infection rates.

BioFuse Medical Technologies, Inc. is privately held and interested accredited investors may learn more about investment opportunities in the Company's 506(c) offering by visiting:

https://www.biofusemedical.com/contact/

Contact:

Scott Sanders, President
BioFuse Medical Technologies, Inc.
[email protected]

SOURCE: BioFuse Medical Technologies, Inc.

Topic:
Company Update
Back to newsroom
Back to Newsroom
Share by: